New trials, publications, preprints and grants on this target, month by month.
Publication
SLIT2 and ANGPTL3 as putative mediators linking obesity to atrial fibrillation: A Mendelian randomization study.
3 Jul 2026· Medicine· PUBMED
Publication
Gene Silencing of ANGPTL3 Induces PCSK9: Exploring the Biological Significance in the Hepatoma Huh7 Cell Line.
30 Jun 2026· Cells· PUBMED
Publication
Anti-ANGPTL3 antibody and IL-22 fusion protein mitigate nephrotic syndrome via mitochondrial protection, anti-apoptosis, and autophagy suppression.
16 Jun 2026· Antibody therapeutics· PUBMED
Publication
Targeting ANGPTL3 and IL-33/ST2 Ameliorates Diabetic Kidney Disease by Reducing Lipotoxicity, Alleviating Inflammation and Inhibiting Fibrosis.
19 May 2026· Advanced science (Weinheim, Baden-Wurttemberg, Germany)· PUBMED
Publication
Promise of ANGPTL3 as a therapeutic target for controlling cholesterol levels.
12 May 2026· Expert opinion on therapeutic targets· PUBMED
Publication
Correction: The ANGPTL3-integrin α5 axis drives retinal vascular leakage in diabetic retinopathy.
9 May 2026· Journal of translational medicine· PUBMED
Publication
Associations of ANGPTL3/4/8 proteins and complexes with heart failure and heart failure mortality.
7 May 2026· Lipids in health and disease· PUBMED
Publication
Apolipoprotein A2 Influences ANGPTL3 in Modulating TG Catabolism and Inflammatory Cytokines Secretion.
4 May 2026· Current molecular medicine· PUBMED
Publication
ANGPTL3, Apo CIII, Leptin and Triglycerides Are Elevated in Metastatic Prostate Cancer.
7 Apr 2026· Cancers· PUBMED
Trial
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
24 Mar 2026· PHASE1 · RECRUITING· CTGOV
Publication
Hepatocyte-Specific Knockout of YAP Protects Against Atherosclerosis via Inhibition of ANGPTL3 in Mice.
26 Feb 2026· Arteriosclerosis, thrombosis, and vascular biology· PUBMED
Trial
A Dose-exploration Study of EDP167 in HoFH
6 Feb 2026· PHASE2 · RECRUITING· CTGOV
Publication
ANGPTL3 in Podocytes Contributes to the Pathogenesis of Lupus Nephritis by Activating MSR1 in Macrophages.
3 Feb 2026· Kidney diseases (Basel, Switzerland)· PUBMED
Publication
ANGPTL3 in the Peripheral Circulation Is Associated with Resistance to Anti-PD1 Therapy in Advanced Gastric Cancer.
1 Feb 2026· Cancer research communications· PUBMED
Publication
Anti-ANGPTL3 Antibody SHR-1918 for Homozygous Familial Hypercholesterolemia: A Nonrandomized Clinical Trial.
1 Feb 2026· JAMA cardiology· PUBMED
Publication
The ANGPTL3-integrin α5 axis drives retinal vascular leakage in diabetic retinopathy.
19 Jan 2026· Journal of translational medicine· PUBMED
Publication
PCSK9 and ANGPTL3 Inhibitors in Homozygous Familial Hypercholesterolemia: A Meta-analysis of Randomized Clinical Trials.
7 Jan 2026· Drugs· PUBMED
Publication
Does siRNA therapy against ANGPTL3 bring new hope in homozygous familial hypercholesterolaemia?
18 Dec 2025· The lancet. Diabetes & endocrinology· PUBMED
Publication
Zodasiran, an RNAi therapeutic targeting ANGPTL3, for treating patients with homozygous familial hypercholesterolaemia (GATEWAY): an open-label, randomised, phase 2 trial.
18 Dec 2025· The lancet. Diabetes & endocrinology· PUBMED
Publication
ANGPTL3 promotes colorectal carcinoma progression and metastasis through regulating COL1A2 transcription via interacting with integrin αVβ3.
17 Nov 2025· Cancer letters· PUBMED
Publication
Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3.
8 Nov 2025· The New England journal of medicine· PUBMED
Publication
Digoxin targets BHLHE40 to inhibit epithelial-mesenchymal transition in cervical cancer cells via downregulation of ANGPTL3.
5 Nov 2025· Journal of natural medicines· PUBMED